25016-20-0

Basic information

• Product Name: 1-Methyl-1H-pyrazole-3-carboxylic acid
• Synonyms: ART-CHEM-BB B000139;AKOS PAO-0549;AKOS B000139;1-METHYLPYRAZOLE-3-CARBOXYLIC ACID;1-METHYL-1H-PYRAZOLE-3-CARBOXYLIC ACID;TIMTEC-BB SBB000008;1-methyl-1H-pyrazole-3-carboxylic acid(SALTDATA: FREE);3-Carboxy-1-methyl-1H-pyrazole
• CAS NO: 25016-20-0
• Molecular Formula: C₅H₆N₂O₂
• Molecular Weight: 126.11
• Product Categories: Building Blocks;Pyrazole
• Mol File: 25016-20-0.mol
• Article Data: 7

Chemical Properties

• Melting Point: 150-152 ºC
• Boiling Point: 306.9 °C at 760 mmHg
• Flash Point: 139.4 °C
• Appearance: /
• Density: 1.34 g/cm³
• Vapor Pressure: 0.000326mmHg at 25°C
• Refractive Index: 1.59
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 4.05±0.10(Predicted)
• CAS DataBase Reference: 1-Methyl-1H-pyrazole-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methyl-1H-pyrazole-3-carboxylic acid(25016-20-0)
• EPA Substance Registry System: 1-Methyl-1H-pyrazole-3-carboxylic acid(25016-20-0)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-36/37/38
• Safety Statements: 22-26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 25016-20-0(Hazardous Substances Data)

Usage

General Description

1-Methyl-1H-pyrazole-3-carboxylic acid is a specialized chemical compound, often used in various organic and pharmaceutical syntheses. It features a pyrazole core, which is a heterocyclic aromatic organic compound that has both pharmaceutical and industrial applications. 1-Methyl-1H-pyrazole-3-carboxylic acid is known for its versatility as it can be used to create a wide range of other pyrazole derivatives. Its molecular formula is C6H7N2O2. Like other carboxylic acids, it possesses acidic properties. It is typically available in a fine powder form which must be carefully handled due to it potentially being harmful if swallowed, inhaled, or in contact with skin. It is generally synthesized under controlled laboratory conditions.

InChI:InChI=1/C5H6N2O2/c1-7-3-2-4(6-7)5(8)9/h2-3H,1H3,(H,8,9)

Upstream product

• 1621-91-6 1H-pyrazole-3-carboxylic acid 
• 77-78-1 dimethyl sulfate 
• 1621-91-6 1-2H-pyrazole-3-carboxylic acid 
• 17827-61-1 methyl ester of 1-methylpyrazole-3-carboxylic acid 

Downstream Products

• 17827-61-1 methyl ester of 1-methylpyrazole-3-carboxylic acid 
• 6647-98-9 4-iodo-1-methyl-1H-pyrazole-3-carboxylic acid 
• 875553-40-5 N-methoxy-N,1-dimethyl-1H-pyrazole-3-carboxamide 
• 1005784-18-8 N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-fluorophenyl]-1-methyl-1H-pyrazole-3-carboxamide 
• 1159996-96-9 (R)-(1-methyl-1H-pyrazol-3-yl)(1-(4-(trifluoromethyl)phenyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone 
• 27258-32-8 1-methyl-1H-pyrazole-3-carbaldehyde 
• 84547-62-6 (1-methyl-1H-pyrazol-3-yl)methanol 
• 88529-80-0 3-(chloromethyl)-1-methyl-1H-pyrazole hydrochloride 
• 84547-72-8 1-methyl-3-(p-nitrostyryl)pyrazole 
• 84547-91-1 4-bromo-1-methyl-5-nitropyrazole-3-carboxylic acid 
• 132668-85-0 trans, trans-1,4-bis<2-(1-methylpyrazol-3-yl)vinyl>benzene 

Relevant articles and documents

Adenosine receptor antagonists

The invention provides a compound shown as a formula (I) and a pharmaceutical composition thereof. The compounds of formula (I) of the present invention are useful as adenosine receptor inhibitors, especially A2A and/or A2B inhibitors, for example, the product can be used for prevention or treatment of diseases associated with A2A and/or A2B activity or expression.

ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2

We have developed a series of novel potent ortho-substituted azole derivatives active against kinases VEGFR-1 and VEGFR-2. Both specific and dual ATP-competitive inhibitors of VEGFR-2 were identified. Kinase activity and selectivity could be controlled by varying the arylamido substituents at the azole ring. The most specific molecule (17) displayed >10-fold selectivity for VEGFR-2 over VEGFR-1. Compound activities in enzymatic and cell-based assays were in the range of activities for reported clinical and development candidates (IC50 30 × 10-5 cm/min) is indicative of their potential for intestinal absorption upon oral administration.

4(SPIROPIPERIDINYL)METHYL SUBSTITUTED PYRROLIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

3-Substituted pyrrolidines having a spiropiperidinylmethyl substituent on the 4-position of the ring are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.